SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, announced today that the company will be participating in the upcoming William Blair 44th Annual Growth Stock Conference.
iRhythm’s management is scheduled to present on Wednesday, June 5, at 11:20 a.m. Central Time. Interested parties may access a live and archived webcast of the presentation on the “Events & Presentations” section of the company’s investor website at investors.irhythmtech.com.
About iRhythm Technologies, Inc.
iRhythm is a leading digital health care company that creates trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable information. Through a relentless focus on patient care, iRhythm’s vision is to deliver better data, better insights, and better health for all.
Investor Relations Contact
Stephanie Zhadkevich
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Kassandra Perry
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$99.97 |
| Daily Change: | 0.02 0.02 |
| Daily Volume: | 24,992 |
| Market Cap: | US$3.130B |
February 20, 2025 December 30, 2024 October 30, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
